Loading stock data…
4519.T
TSE¥7,445-1400.00 (-15.83%)
Market ClosedLast close Apr 27
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Chugai Pharmaceutical Co., Ltd. in the Healthcare sector is trading at ¥7,445. The stock is currently 30% below its 52-week high of ¥10,700, remaining 4.7% below its 200-day moving average. Technical signals show neutral RSI of 30 and bearish MACD signal, explaining why 4519.T maintains its current current market pressure. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 30) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price¥7,445
Potential Downside
33.8%
Whystock Fair Value¥4,931
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Buy
Mean target¥10,050+35.0%
Range¥7,600 – ¥13,300
Fundamentals
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Ava...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
¥14.69T
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
33.85
Beta
Defensive asset. Lower volatility than the S&P 500.
0.60
Div Yield
Strong income play. Yield provides a meaningful total return floor.
151.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.10%
Volume
Today's trading volume
10.09M
Recent News
Is Chugai Pharmaceutical (TSE:4519) Still Attractively Priced After Its Strong Multi Year Run
Wondering if Chugai Pharmaceutical's share price still offers value after a strong multi year run? This article unpacks how the current price compares with several valuation checks. The stock last closed at ¥8,585, with a 3.2% decline over the past week and an 8.3% decline over the past month. It is still up 0.8% year to date and 34.6% over 1 year, and very large over 3 and 5 years. Recent coverage has focused on Chugai Pharmaceutical's position within the pharmaceuticals space in Japan and...
Rani Therapeutics Q4 Earnings Call Highlights
Rani Therapeutics (NASDAQ:RANI) executives highlighted what they described as a “transformational” 2025 during the company’s fourth-quarter and full-year earnings call, pointing to progress advancing its oral biologics delivery platform, the launch of a new clinical study, and a new strategic collab
Roche stops work on experimental SMA drug
In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not consistently” improving muscle growth and motor function in a key study.
Why Sarepta Therapeutics (SRPT) Is Down 11.2% After CEO Retirement Plan And Japan Gene Therapy Launch - And What's Next
In late February 2026, Sarepta Therapeutics reported fourth‑quarter 2025 revenue of US$442.93 million and a net loss of US$412.23 million, while CEO Douglas Ingram notified the company of his plan to retire by the end of 2026 or upon appointment of a successor. At the same time, Sarepta and partner Chugai launched ELEVIDYS, Japan’s first gene therapy for Duchenne muscular dystrophy, underscoring the company’s ongoing commercial pivot amid leadership transition and recent safety‑related...
Assessing Chugai Pharmaceutical (TSE:4519) Valuation Following Strong Share Price Gains
Chugai Pharmaceutical (TSE:4519) has delivered a steady annual revenue growth of nearly 5% and net income growth close to 9% recently. Investors keep a keen eye on these metrics as the healthcare landscape in Japan continues to evolve. See our latest analysis for Chugai Pharmaceutical. Chugai Pharmaceutical’s share price has shown impressive momentum this year, recently jumping 8.25% over the past week and adding 20.24% in the last three months. The company’s performance has translated into a...